Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by William Abramovits
Based on 11 articles published since 2010
(Why 11 articles?)
||||

Between 2010 and 2020, W. Abramovits wrote the following 11 articles about Psoriasis.
 
+ Citations + Abstracts
1 Review Ilumya® (Tildrakizumab): A Newly Approved Interluekin-23 Antagonist for the Treatment of Plaque Psoriasis. 2018

Gupta, Aditya K / Versteeg, Sarah G / Abramovits, William / Vincent, Kimberly D. ·Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada; agupta@execulink.com. · Mediprobe Research Inc., London, Ontario, Canada. · Department of Medicine, Baylor University Medical Center, University of Texas Southwestern Medical School. · Department of Dermatology, University of Texas Southwestern Medical School. · Department of Family Practice, University of Texas Southwestern Medical School. · Dermatology Treatment and Research Center, Dallas, TX. · Belle Meade Dermatology, Nashville, TN. ·Skinmed · Pubmed #30413226.

ABSTRACT: -- No abstract --

2 Review XELJANZ (Tofacitinib) for Chronic Plaque Psoriasis. 2015

Gupta, Aditya K / Daigle, Deanne / Abramovits, William / Vincent, Kimberly Dawn. · ·Skinmed · Pubmed #26380510.

ABSTRACT: -- No abstract --

3 Review Topical vitamin D analogs available to treat psoriasis. 2012

Oquendo, Marcial / Abramovits, William / Morrell, Peter. ·Dermatology Treatment and Research Center, 5310 Harvest Hill Road, Suite 160, Dallas, TX 75230, USA. dr.oquendo@gmail.com ·Skinmed · Pubmed #23346664.

ABSTRACT: Psoriasis is a chronic and currently incurable inflammatory skin disease, affecting 2% to 3% of the US population. The cost of care in the United States for hospitalizations, outpatient physician visits, phototherapy, prescription therapies, and over-the-counter medications is estimated to be more than $650 million per year. Guidelines developed by the American Academy of Dermatology in 2009 state that approximately 80% of these patients with psoriasis have mild to moderate disease that can be managed with topical agents, including corticosteroids and vitamin D analogs. Topical vitamin D analogs provide "steroid-sparing" effects and a favorable safety profile. Many experts, including a recent consensus conference, classify topical vitamin D agents as first-line therapy for psoriasis either as monotherapy or in combination with topical steroids due to a synergistic, complementary effectiveness. Vitamin D analogs are an indispensable component of the current physician's armamentarium for psoriasis treatment. This review, therefore, is oriented to give a comprehensive understanding of this group of drugs and display the available clinical data for each formulation.

4 Clinical Trial Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. 2017

Blauvelt, A / Reich, K / Mehlis, S / Vanaclocha, F / Sofen, H / Abramovits, W / Zhao, Y / Gilloteau, I / Davenport, E / Williams, N / Guana, A / Tyring, S. ·Oregon Medical Research Center, Portland, OR, USA. · Dermatologikum Hamburg and SCIderm GmbH, Hamburg, Germany. · NorthShore University Health System, Skokie, IL, USA. · Dermatology Department, Hospital Universitario, Madrid, Spain. · Department of Medicine (Dermatology) UCLA, Los Angeles, CA, USA. · Baylor University Medical Center, Dallas, TX, USA. · Formerly with Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. · Novartis Pharma AG, Basel, Switzerland. · RTI Health Solutions, Research Triangle Park, NC, USA. · Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. · University of Texas Health Science Center for Clinical Studies, Houston, TX, USA. ·J Eur Acad Dermatol Venereol · Pubmed #28602039.

ABSTRACT: BACKGROUND: Psoriasis can greatly impact patients' lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin-17A, has demonstrated good efficacy and safety in the treatment of moderate-to-severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response. OBJECTIVE: This analysis using the CLEAR study, a phase 3b double-blind study comparing the efficacy and safety of secukinumab vs. ustekinumab in adults with moderate-to-severe plaque psoriasis, evaluated the treatment effects on patient's daily activities and personal relationships. METHODS: Impact on daily activities (interference with home/shopping/garden, and influence on clothes worn) and impact on personal relationships (problems with partner/others, and sexual difficulties) as well as their corresponding subscales were selected from the Dermatology Life Quality Index scale and evaluated for patients treated with secukinumab vs. ustekinumab from the CLEAR study. Treatment differences in mean scores and proportions of responders (score = 0, indicating no impact) were evaluated through 52 weeks. Time to response was evaluated through Week 16. RESULTS: Significant differences between secukinumab and ustekinumab were observed for daily activities and personal relationships at Week 16 and sustained through Week 52 (Week 52 response rates for daily activities: 82.9% vs. 73.5%, including interference with home/shopping/garden: 88.5% vs. 78.2%, and influence on clothes worn: 85.6% vs. 74.4%; personal relationships: 86.1% vs. 73.7%, including problems with partner/others: 86.6% vs. 74.8%, and sexual difficulties: 88.5% vs. 74.3%; all P < 0.01). The median time to response was 4 weeks for secukinumab vs. 8 weeks for ustekinumab for daily activities and personal relationships (both P < 0.05). CONCLUSION: Secukinumab treatment helps patients with moderate-to-severe plaque psoriasis have a more normal life faster when compared to ustekinumab, by providing greater and sustained improvement in clothing choice and sexual functioning.

5 Article Tremfya™ (Guselkumab). 2019

Abramovits, William / Wiqas, Ali / Vincent, Kimberly Dawn / Versteeg, Sarah G / Gupta, Aditya K. ·Department of Medicine, Baylor University Medical Center, University of Texas Southwestern Medical School. · Department of Dermatology, University of Texas Southwestern Medical School. · Department of Family Practice, University of Texas Southwestern Medical School. · Dermatology Treatment and Research Center, Dallas, TX. · Texas College of Osteopathic Medicine, Fort Worth, TX. · Belle Meade Dermatology, Nashville, TN. · Mediprobe Research Inc., London, Ontario, Canada. · Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada. ·Skinmed · Pubmed #30888946.

ABSTRACT: -- No abstract --

6 Article Cimzia™ (Certolizumab Pegol). 2018

Abramovits, William / Wiqas, Ali / Vincent, Kimberly Dawn / Versteeg, Sarah G / Gupta, Aditya K. ·Department of Medicine, Baylor University Medical Center, Dallas, TX. · Department of Dermatology, University of Texas Southwestern Medical School, Dallas, TX. · Department of Family Practice, University of Texas Southwestern Medical School, Dallas, TX. · Dermatology Treatment and Research Center, Dallas, TX. · Texas College of Osteopathic Medicine, Fort Worth, TX. · Belle Meade Dermatology, Nashville, TN. · Mediprobe Research Inc., London, Ontario, Canada. · Mediprobe Research Inc., London, Ontario, Canada; agupta@execulink.com. · Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada. ·Skinmed · Pubmed #30575508.

ABSTRACT: -- No abstract --

7 Article T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. 2018

Winthrop, Kevin L / Korman, Neil / Abramovits, William / Rottinghaus, Scott T / Tan, Huaming / Gardner, Annie / Mukwaya, Geoffrey / Kaur, Mandeep / Valdez, Hernan. ·Oregon Health and Science University, Portland, Oregon. Electronic address: winthrop@ohsu.edu. · University Hospitals Case Medical Center, Cleveland, Ohio. · Dermatology Treatment and Research Center, Dallas, Texas. · Pfizer Inc, Groton, Connecticut. · Pfizer Inc, Cambridge, Massachusetts. · Pfizer Inc, New York, NY. · Pfizer Inc, Collegeville, Pennsylvania. ·J Am Acad Dermatol · Pubmed #29080806.

ABSTRACT: BACKGROUND: Psoriasis is often treated with immunomodulatory therapies that can affect the immune response to common antigens. Tofacitinib is an oral Janus kinase inhibitor. OBJECTIVE: To characterize the effect of long-term exposure to tofacitinib 10 mg twice daily on T-cell function in psoriasis patients. METHODS: Patients completing at least 3 months' continuous treatment with tofacitinib 10 mg twice daily were vaccinated with T-cell-dependent vaccines (monovalent tetanus toxoid and 13-valent pneumococcal conjugate [PCV-13]). Patients were assessed at baseline (before vaccination) and then again 4 weeks after vaccination. For PCV-13, we evaluated serotype-specific, opsonophagocytic antibody responses, and for tetanus toxoid, we evaluated humoral responses. RESULTS: Among 60 patients who completed the study, the geometric mean fold rise from baseline for the 13 PCV serotypes at 4 weeks postvaccination varied from 8.3 (serotype 3) to 101.9 (serotype 6A). Similar results were observed for patients with and without lymphopenia at baseline. For tetanus toxoid, 51 (88%) patients had ≥2-fold and 35 (60%) patients had ≥4-fold rise in antibody concentration. LIMITATIONS: There was no placebo control. CONCLUSION: Most psoriasis patients who receive tofacitinib can mount satisfactory T-cell-dependent responses to PCV-13 and tetanus vaccines.

8 Article Brodalumab (Siliq 2017

Gupta, Aditya K / Versteeg, Sarah Versteeg / Abramovits, William / Vincent, Kimberly D. ·Department of Medicine, University of Toronto School of Medicine, Toronto; agupta@execulink.com. · Mediprobe Research Inc., London. · Ontario, Canada; the Department of Medicine, Baylor University Medical Center. · Departments of Dermatology and Family Practice, University of Texas Southwestern Medical School. · Dermatology Treatment and Research Center. · Dallas, TX; and Private Practice, Belle Meade Dermatology, Nashville, TN. ·Skinmed · Pubmed #28859739.

ABSTRACT: -- No abstract --

9 Article Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. 2017

Menter, Alan / Thaçi, Diamant / Wu, Jashin J / Abramovits, William / Kerdel, Francisco / Arikan, Dilek / Guo, Dianlin / Ganguli, Arijit / Bereswill, Mareike / Camez, Anne / Valdecantos, Wendell C. ·Division of Dermatology, Baylor University Medical Center, Dallas, TX, USA. amderm@gmail.com. · Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, Campus Lübeck, Germany. · Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA. · Dermatology Treatment and Research Center, Dallas, TX, USA. · Florida Academic Dermatology Centers, Miami, FL, USA. · AbbVie Inc, North Chicago, IL, USA. · AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany. ·Dermatol Ther (Heidelb) · Pubmed #28815476.

ABSTRACT: INTRODUCTION: ESPRIT (NCT00799877) is an ongoing 10-year international prospective observational registry evaluating the long-term safety and effectiveness of originator adalimumab in routine clinical practice for adult patients with chronic plaque psoriasis. Herein, we report the long-term safety, effectiveness, and patient-reported outcomes (PROs) following adalimumab treatment over the first 7 years of the ESPRIT registry. METHODS: All treatment-emergent (All-TE) adverse events (AE) since the initial (first ever) dose of adalimumab were assessed. Physician Global Assessment (PGA) and PROs (PROs for US patients only) were evaluated during registry participation. RESULTS: As of 30 November 2015, 6051 patients in the ESPRIT registry were analyzed, representing 23,660.1 patient-years (PY) of overall adalimumab exposure. The incidence rates for All-TE serious AEs, serious infections, and malignancies were 4.4, 1.0, and 1.0 events per 100 PY (E/100PY), respectively. The standardized mortality ratio for TE deaths in the registry was 0.27 (95% CI 0.18-0.38). During the registry's first 7 years, PGA "clear" or "minimal" was achieved by >50% of patients at each annual visit, and among US patients, the mean improvement from baseline in different PROs was maintained. CONCLUSION: No new safety signals were identified during the first 7 years of the registry, and safety was consistent with the known safety profile of adalimumab. The number of TE deaths was below the expected rate. During the registry's first 7 years, most of the patients remained free of All-TE cardiovascular events, serious infections, and malignancy. As-observed effectiveness of adalimumab and improvements from baseline in PROs were maintained through 7 years of registry participation. FUNDING: Abbvie. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT00799877.

10 Article COSENTYX (Secukinumab). 2015

Gupta, Aditya K / Foley, Kelly A / Abramovits, William. ·Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada. · Mediprobe Research Inc, London, Ontario, Canada; agupta@execulink.com. · Mediprobe Research Inc, London, Ontario, Canada. · Department of Medicine, Baylor University Medical Center, Dallas, TX. · Departments of Dermatology and Family Practice, University of Texas Southwestern Medical School, Dallas, TX. · Dermatology Treatment and Research Center, Dallas, TX. ·Skinmed · Pubmed #26861430.

ABSTRACT: -- No abstract --

11 Article Sorilux (calcipotriene) foam 0.005%. 2012

Abramovits, William / Oquendo, Marcial / Scheinfeld, Noah / Gupta, Aditya K. ·Department of Medicine, Baylor University Medical Center, USA. dra@dermcenter.us ·Skinmed · Pubmed #23163073.

ABSTRACT: -- No abstract --